Senolytic drugs unexpectedly damage brain cells that make myelin

Key Findings

🔬 Mitochondrial DNA links cellular aging to chronic inflammation

• Researchers identified mitochondrial DNA (mtDNA) as a key "bridge" connecting two major aging processes: cellular senescence and chronic inflammation

• When mtDNA leaks from damaged mitochondria into the cell's interior or outside the cell, it triggers inflammatory responses that amplify the aging process

• The study proposes targeting mtDNA dynamics as a potential therapeutic strategy for age-related diseases

📊 Aging gut transfers to young mice, shortening their lifespan

• Adult mice given fecal transplants from old mice developed higher anxiety, impaired immune function, and increased inflammatory stress—effects that persisted into old age

• The "aged microbiota" group showed higher biological age markers and reduced longevity compared to controls

• Key bacterial changes included increases in Akkermansia, Anaerostipes, Dubosiella, and Ruminococcus species

🎯 AI predicts cellular aging from tissue images alone

• TLPath, a deep learning system trained on 5,000+ tissue images from 919 people across 18 organs, can predict telomere length (a cellular aging marker) just from looking at tissue structure

• The AI achieved a correlation of 0.51 with actual telomere measurements—better than using chronological age as a predictor

• The system identified shortened telomeres in people with type 1 and type 2 diabetes across multiple tissues, which was confirmed experimentally

💊 First clinical trial tests senolytic for cancer survivors

• The TROFFi study will test fisetin (20 mg/kg/day for 4 cycles) in 88 postmenopausal breast cancer survivors with reduced physical function after chemotherapy

• Participants must have completed chemotherapy within 12 months and walk less than 400 meters in 6 minutes to qualify

• The trial targets chemotherapy-induced cellular senescence as a potential cause of persistent physical decline

🧬 Neighborhood poverty linked to cellular aging markers

• Among 1,215 U.S. adults, those living in low-opportunity neighborhoods had significantly elevated CDKN2A RNA (a cellular senescence marker) compared to high-opportunity areas

• The association was strongest for social and economic resources rather than education or health/environment factors

• No significant relationships were found with other aging markers like DNA damage response or inflammatory secretions

🔋 NAD+ supplements need weeks to reach the brain

• In a phase I trial with 12 participants (6 healthy, 6 with Parkinson's), blood NAD+ levels increased slowly over 2 weeks with 1,200 mg/day nicotinamide riboside or mononucleotide

• Brain NAD+ levels didn't increase until after 4 weeks of treatment, with similar slow decline after stopping

• NAD+ responses varied widely between individuals but weren't affected by disease status or sex